Loomis, Sayles & Company
IRWD icon

Loomis, Sayles & Company’s Ironwood Pharmaceuticals IRWD Stock Holding History

Loomis, Sayles & Company’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,818,123
Closed -$28.1M – 883
2018
Q3 		$28.1M Sell
1,818,123
-6,936
-0.4% -$110K 0.06% 166
2018
Q2 		$29.2M Sell
1,825,059
-6,242
-0.3% -$92.4K 0.06% 158
2018
Q1 		$23.7M Sell
1,831,301
-55,048
-3% -$686K 0.05% 198
2017
Q4 		$23.7M Buy
1,886,349
+33,939
+2% +$443K 0.05% 229
2017
Q3 		$24.5M Sell
1,852,410
-53,745
-3% -$740K 0.05% 227
2017
Q2 		$30.1M Buy
1,906,155
+11,345
+0.6% +$165K 0.07% 169
2017
Q1 		$27.1M Sell
1,894,810
-41,604
-2% -$569K 0.07% 185
2016
Q4 		$24.8M Buy
1,936,414
+89,568
+5% +$1.13M 0.06% 208
2016
Q3 		$24.6M Sell
1,846,846
-359,703
-16% -$4.21M 0.06% 203
2016
Q2 		$24.2M Buy
2,206,549
+237,438
+12% +$2.32M 0.07% 220
2016
Q1 		$18M Buy
1,969,111
+154,814
+9% +$1.28M 0.05% 302
2015
Q4 		$17.6M Buy
+1,814,297
New +$17.5M 0.05% 325

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company's IRWD Position: Q4 2018 in Review

Loomis, Sayles & Company sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2018, closing a stake of 1,818,123 shares — an estimated $28.1M sold.

Loomis, Sayles & Company first reported a position in IRWD in Q4 2015 and held it in 12 quarters. The position peaked at $30.1M in Q2 2017. 145 funds tracked by Wall St. Rank hold IRWD as of Q4 2018.

  • Loomis, Sayles & Company reported no remaining Ironwood Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,818,123 Ironwood Pharmaceuticals shares in Q4 2018, an estimated $28.1M.
  • Loomis, Sayles & Company first reported a position in Ironwood Pharmaceuticals in Q4 2015 and held it in 12 quarters.
  • Loomis, Sayles & Company's Ironwood Pharmaceuticals position peaked at $30.1M in Q2 2017.
  • 145 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2018.

Based on Loomis, Sayles & Company's 13F filing for Q4 2018, filed 14 Feb 2019.